Income Taxes - Additional information (Details) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Oct. 24, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Income Taxes | |||
| Operating Loss Carryforwards | $ 828,000,000 | ||
| Deferred tax assets, Tax credit carry forward unused research and development | 506,700,000 | ||
| Research and development credit carry forwards | 19,746,000 | $ 18,687,000 | |
| Deferred tax liabilities Intangible assets | 12,970,000 | ||
| Uncertain tax positions | 0 | 0 | |
| Amounts accrued for penalties or interest | 0 | 0 | |
| Advent BioServices | |||
| Income Taxes | |||
| Intangible assets | $ 51,518,000 | 52,000,000 | |
| Gain (loss) on sale of intangible asset | 52,000,000 | ||
| Sale Of Intangible Assets | $ 52,000,000 | 52,000,000 | |
| Foreign Tax Authorities | |||
| Income Taxes | |||
| Operating Loss Carryforwards | 321,300,000 | ||
| Change in valuation allowance | 1,532,000 | $ 1,213,000 | |
| Tax credit carryforwards for foreign tax | 27,700,000 | ||
| U.K | |||
| Income Taxes | |||
| Tax credit carryforwards for foreign tax | $ 9,000,000 | ||
| Foreign tax rate | 25.00% | ||
| Germany. | |||
| Income Taxes | |||
| Tax credit carryforwards for foreign tax | $ 18,700,000 | ||
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible unused research and development tax credit carryforwards. No definition available.
|
| X | ||||||||||
- Definition Amount of estimated gain (loss) on sale of intangible asset. No definition available.
|
| X | ||||||||||
- Definition Percentage of foreign tax rate applicable to pretax income (loss). No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of stepped up value upon sale of intangible assets. No definition available.
|
| X | ||||||||||
- Definition Amount of identifiable intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of unrecognized tax benefits. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|